Mind Medicine (MindMed) Inc. announced that it has completed enrollment of Study MMED007, the Company's Phase 2a study evaluating repeated low-dose administration of MM-120 (lysergide D-tartrate) for the treatment of adults with ADHD. MMED007 is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MM-120 (20 mg) compared with a placebo administered orally twice weekly for 6 weeks in adults between the ages of 18 and 65 with ADHD.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.03 USD | +5.99% | +4.03% | +146.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+146.72% | 649M | |
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder